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MaOBJECTIVES This study sought to compare the outcomes of spot stenting versus long stenting after intentional
subintimal approach for long femoropopliteal chronic total occlusions (CTO).
BACKGROUND The optimal stenting strategy following the subintimal recanalization of long femoropopliteal chronic
total occlusions has not been investigated.
METHODS A total of 196 limbs in 163 patients, implanted with bare nitinol stents after subintimal approach in long
femoropopliteal occlusions (lesion length 25  8 cm), were retrospectively analyzed. The primary patency was compared
between spot stenting (n ¼ 129) and long stenting (n ¼ 67).
RESULTS Baseline characteristics and immediate procedural results were similar between groups. Adjusted-primary
patency (47% vs. 77%, p < 0.001) and adjusted-freedom from target lesion revascularization (52% vs. 84%, p < 0.001)
at 2 years were signiﬁcantly lower in the long stenting group than in the spot stenting group. The incidence of stent
fracture, fracture type, and restenosis pattern did not differ between groups. Long stenting was an independent predictor
of restenosis (hazard ratio [HR]: 2.0) along with other risk factors such as nonuse of clopidogrel (HR: 3.3) or cilostazol
(HR: 2.2), small stent diameter (HR: 0.6), poor run-off (HR: 1.9), and post-procedural ankle-brachial index (HR: 0.1).
Compared with spot stenting after adjustment using inverse probability of treatment weighting, long stenting, especially
involving the P2 or P3 segment of the popliteal artery, was independently associated with 7.5-fold increases in restenosis
risk (p < 0.001).
CONCLUSIONS The primary patency was signiﬁcantly higher with spot stenting than with long stenting following
subintimal approach for long femoropopliteal chronic total occlusions. The risk of restenosis was especially higher when
long stenting was extended to the distal popliteal artery. (J Am Coll Cardiol Intv 2015;8:472–80) © 2015 by the
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AB BR E V I A T I O N S
AND ACRONYM S
ABI = ankle-brachial index
CT = computed tomography
CTO = chronic total occlusion
HR = hazard ratio
SFA = superﬁcial femoral
artery
TASC = TransAtlantic Inter-
Societal Consensus
TLR = target lesion
revascularization
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473R ecent randomized studies have revealed thatstent placement is associated with improvedpatency and clinical improvement compared
with balloon angioplasty for the endovascular treat-
ment of superﬁcial femoral artery (SFA) lesions of
increasing lengths (1–3). However, most of these pa-
tients had stenotic lesions rather than occlusions,
and long lesions were rarely included. Therefore,
treatment strategies for long occlusions of the SFA
have not been standardized, although these occlu-
sions are relatively common in patients with lower
extremity artery disease (4,5). Subintimal angioplasty
is a widely accepted treatment approach for the
recanalization of long chronic total occlusions (CTO)
of the SFA with favorable immediate and late out-
comes (6–10). Despite the frequent use of subintimal
angioplasty for CTO lesions of the SFA, the role of
stenting in the subintimal tract is unclear. Whether
spot stenting, which only covers segments with ﬂow
limitations or residual stenosis >30%, or long stent-
ing, which covers the whole subintimal tract, is supe-
rior remains unknown, and an optimal stenting
strategy has yet to be determined. Therefore, the pur-
pose of this study was to compare the outcomes of
spot stenting versus long stenting after subintimal
approach for long CTO of the femoropopliteal artery.SEE PAGE 481METHODS
SUBJECTS. Between 2003 and 2013, a total of 196
limbs in 163 patients who underwent successful
stenting after intentional subintimal approach for
long femoral CTO (lesion length $8 cm) were retro-
spectively analyzed. The treated limbs were classiﬁed
into 2 groups, according to the stenting strategies: 129
limbs (66%) in the spot stenting group and 67 limbs
(34%) in the long stenting group.
Before the angioplasty procedure, all patients un-
derwent physical examinations, ankle-brachial index
(ABI) assessments, and imaging tests, including
computed tomography (CT), magnetic resonance
angiography, or color duplex ultrasound. The Insti-
tutional Review Board at the Severance Hospital of
the Yonsei University Health System approved this
study and waived the requirements for informed
consent for this retrospective analysis.
ANGIOPLASTY PROCEDURE. All procedures were
performed under local anesthesia supplemented with
intravenous sedation and analgesia when required.
Either ipsilateral or contralateral femoral puncture
was performed, depending on the distance to thetarget lesion. A 7-F introducer sheath (Ter-
umo, Tokyo, Japan) was used for the ipsilat-
eral approach, whereas a contralateral sheath
(6-F to 8-F, Balkin; Cook Inc., Bloomington,
Indiana) was employed for the crossover
approach. A 0.035-inch hydrophilic guide-
wire (Radifocus, Terumo) and a supporting
5-F multipurpose catheter (Torkon NB, Cook
Inc.) were used to cross the totally occluded
lesion. In the intentional subintimal ap-
proach, a straight hydrophilic 0.035-inch wire
was introduced at the level of the proximal
stump eccentrically either into the medial or
lateral wall of the occluded femoral artery using a 4-F
or 5-F angled catheter. The wire was advanced
distally to form a loop of wire, which was then pushed
into the distal lumen supported by the catheter. We
considered wire passage to be subintimal when linear
or spiral dissections were visible at the proximal and
distal stump. The Outback LTD re-entry catheter
(Cordis, Bridgewater, New Jersey) was used when
the guidewire failed to enter into the true lumen.
After the subintimal passage of the guidewire through
the CTO, the target artery was dilated with a balloon
(5 to 6 mm in diameter).
The stenting strategy was chosen by the operators’
discretion. In the spot stenting group, the entire
lesion length was not covered with stents after
balloon dilation. At least 1 stent was routinely
deployed into the proximal stump of the subintimal
tract (10), and the segments with ﬂow-limiting
dissection, signiﬁcant residual stenosis (>30%), or a
pressure gradient >20 mm Hg were covered with
additional stents. In the long stenting group, the
entire lesion length was primarily covered with
overlapping stents. Self-expanding nitinol stents
(S.M.A.R.T. [Cordis]; Zilver [Cook]; Absolute Pro
[Abbott Vascular, Redwood City, California]; Com-
plete SE, [Medtronic, Santa Rosa, California]; or Pro-
tégé Everﬂex [Covidien, Plymouth, Minnesota]) of
6 to 8 mm in diameter were deployed into the sub-
intimal channel. Deployed stents were routinely
dilated with balloons for better apposition. After
stenting, we routinely administered the combination
of aspirin (100 mg/day) and either clopidogrel
(75 mg/day) or cilostazol (200 mg/day) for at least
1 year. Thereafter, lifelong aspirin with or without
cilostazol was given.
FOLLOW-UPS AND EVALUATIONS OF STENT-RELATED
FACTORS FOR RESTENOSIS. All patients underwent
noninvasive hemodynamic evaluations before dis-
charge, including ABI measurements, segmental
pressures, and pulse volume recordings. Patients
TABLE 1 Baseline Characteristics According to the Stenting Strategies
Spot
Stenting
129 Limbs
Long
Stenting
67 Limbs p Value* p Value†
Age, yrs 69  9 71  9 0.112 0.181
Male 109 (84) 47 (70) 0.018 0.021
Body mass index, kg/m2 22.9  3.5 22.4  3.3 0.254 0.266
Risk factors
Hypertension 94 (73) 53 (79) 0.339 0.345
Diabetes mellitus 70 (54) 35 (52) 0.788 0.795
Coronary artery disease 85 (66) 38 (57) 0.208 0.219
History of smoking 65 (50) 24 (36) 0.052 0.055
Dyslipidemia 40 (31) 28 (42) 0.133 0.148
Chronic kidney disease 27 (21) 9 (13) 0.199 0.233
Clinical stage of PAD, Rutherford class 0.261 0.271
2 39 (30) 13 (19)
3 49 (38) 23 (34)
4 18 (14) 11 (16)
5 18 (14) 15 (22)
6 5 (4) 5 (7)
Discharge medication
Aspirin 121 (94) 65 (97) 0.499 0.245
Clopidogrel 106 (82) 58 (87) 0.430 0.405
Cilostazol 46 (36) 28 (42) 0.401 0.432
Statin 67 (52) 42 (63) 0.151 0.163
ACE inhibitor or ARB 55 (43) 25 (37) 0.472 0.493
Values are mean  SD or n (%). *For limb basis analysis. †For patient basis analysis and derived
from generalized estimating equations. Of 163 patients, 33 patients received stents at both sides
of limbs (both spot stentings for 17 patients, both long stentings for 5 patients, and spot and long
stenting at each limb for 11 patients).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; PAD ¼ peripheral
artery disease.
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474were observed at 1 month after the procedure and
then were physically examined at 3-month intervals.
Noninvasive hemodynamic evaluations were re-
peated at 1-year intervals or if the symptom status
deteriorated. At least 1 imaging study, such as CT
angiography, duplex ultrasound, or intra-arterial
angiography, was performed in the event of either a
>0.15 decrement in the ABI or worsening symptoms
that were reﬂected by changes in the Rutherford
category.
To evaluate the stent-related factors for restenosis,
the extent of popliteal artery coverage of the distal
stents, a stent-to-artery ratio, a stent fracture, and the
presence of lesion calciﬁcation were analyzed. The
extent of popliteal artery coverage was classiﬁed by
segments (P1, P2, and P3) according to the location of
the distal stent margin (11). The femoral artery size
was calculated from the average diameter of the
proximal and distal stump, where each stump diam-
eter was measured from the long- and short-axis
diameter on the pre-procedural CT images. Stent
fractures were deﬁned as the clear interruption (1 to
2 mm) of stent struts with kinks or misalignmentsalong the axial length of the stent, and they were
classiﬁed as types 1 to 5 (12). For evaluation of stent
fractures, biplane radiographs (anteroposterior and
oblique 30 view) of the implanted stents were ob-
tained at 12 months or at repeat interventions using
ﬂuoroscopy or plain x-ray machine. Calciﬁed lesions
were deﬁned as obvious densities observed within
the apparent vascular wall in the angiogram.
STUDY ENDPOINTS AND DEFINITIONS. Technical
success was deﬁned as recanalization of the target
lesion in the absence of residual stenosis >30% or
ﬂow-limiting dissection. A major complication was
deﬁned as any event that was either fatal or required
surgical management or rehospitalization within
30 days of the procedure. The primary endpoint was
primary patency, which was assessed by intra-arterial
angiography, CT angiography, or duplex ultrasound.
Peak velocity $180 cm/s or a lesion/adjacent segment
velocity ratio $2.4 by duplex was considered to
indicate signiﬁcant ($50%) restenosis. Additionally,
the restenotic patterns were classiﬁed as type 1 (focal
restenosis as #50 mm in length), type 2 (diffuse
restenosis as >50 mm in length), or type 3 (total oc-
clusions) (13). The secondary endpoint was the
freedom of target lesion revascularization (TLR). All
TLR were performed for restenotic lesions with both
worsening symptoms and a >0.15 decrement in the
ABI.
STATISTICAL ANALYSIS. Continuous data are pre-
sented as mean  SD, and categorical data are pre-
sented as counts (percentages). Baseline clinical and
lesion characteristics were compared between the 2
groups using a Student t test for continuous data or
Fisher exact test for categorical data. Primary and
secondary endpoints were estimated using the
Kaplan-Meier survival analysis and compared by log-
rank test. We performed a univariate analysis using
the Cox proportional hazards regression with all var-
iables listed in Tables 1 and 2. The variables achieving
p < 0.1 in the univariate analysis were entered into
the multivariate analysis model. Two models of
multivariate analysis were used to separately eval-
uate the impact of long stenting and the degree of
the popliteal coverage of stenting on the risk of
restenosis. In the ﬁrst model, the long stenting group
was compared with the spot stenting group. In the
second model, the long stenting group was further
classiﬁed into the long stentings limited to femoral
artery, those extended to P1, and those extended to
the P2 or P3 segment, respectively. All variables met
the proportional hazards assumption when we eval-
uated them by including an interaction between
covariates and the logarithm of time and by
TABLE 2 Lesion and Procedural Characteristics According to the Stenting Strategies
Spot
Stenting
129 Limbs
Long
Stenting
67 Limbs p Value* p Value†
Mean lesion length, cm 25.7  8.6 24.2  7.8 0.225 0.224
Proximal SFA 107 (83) 52 (78) 0.365 0.364
Lesions with P2 or P3 segment
involvement
21 (16) 15 (22) 0.295 0.262
Lesion type, TASC II 0.007 0.020
B 3 (2) 8 (12)
C 25 (19) 14 (21)
D 101 (78) 45 (67)
Calciﬁed lesion 36 (28) 24 (36) 0.254 0.258
Right side 57 (44) 33 (49) 0.499 0.483
Distal run-off vessels #1 45 (35) 28 (42) 0.343 0.338
Pre-procedural ABI 0.48  0.17 0.45  0.19 0.494 0.482
Use of re-entry device 5 (4) 5 (7) 0.314 0.284
Number of stents <0.001 <0.001
1 112 (87) 16 (24)
2 17 (13) 42 (63)
3 0 9 (13)
Stented length, cm 10.3  3.6 24.6  8.7 <0.001 <0.001
Mean stent diameter, mm 7.3  0.7 6.5  0.5 <0.001 <0.001
Mean femoral artery diameter, mm‡ 6.2  1.0 5.8  0.9 0.010 0.011
Stent-to-artery ratio‡ 1.2  0.2 1.1  0.2 0.232 0.331
Proximal stent diameter, mm <0.001 <0.001
6 23 (18) 29 (43)
7 54 (42) 32 (48)
8 52 (40) 6 (9)
Stent type 0.165 0.339
S.M.A.R.T. 110 (85) 51 (76)
Zilver 8 (6) 3 (5)
Absolute Pro 3 (2) 5 (8)
Complete SE 2 (2) 4 (6)
Protégé Everﬂex 6 (5) 4 (6)
Extent of popliteal artery stent coverage <0.001 <0.001
Popliteal artery, P1 segment 7 (5) 23 (34)
Popliteal artery, P2 or P3 segment 2 (2) 15 (22)
Values are mean  SD or n (%). *For limb basis analysis. †For patient basis analysis and derived from generalized
estimating equations. ‡Pre-procedural CT angiography was available for 101 lesions in the spot stenting group
and 50 lesions in the long stenting group.
ABI ¼ ankle-brachial index; CT ¼ computed tomography; SFA ¼ superﬁcial femoral artery; TASC ¼
TransAtlantic Inter-Societal Consensus.
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475examination of log (-log [survival]) curves. Consid-
ering that some patients contributed data from >1
limb, generalized estimating equations and clustered
Cox regression analysis were performed.
To reduce the impact of selection bias and potential
confounding in an observational study, adjusted sur-
vival curves and weighted Cox proportional-hazards
regression models were also constructed using
the inverse probability of treatment weighting after
stabilization and trimming (14). Weights for pa-
tients receiving long stenting were the inverse of
(1 – propensity score), and weights for patients
receiving spot stenting were the inverse of the pro-
pensity score. Propensity scores were estimated using
multiple logistic regression analysis. A full non-
parsimonious model was developed that included all
variables in Tables 1 and 2, except number of stents,
stented length, mean femoral artery diameter, stent-
to-artery ratio, and extent of popliteal artery stent
coverage. For stabilization, we multiplied the inverse
probability of treatment weighting weights by the
marginal prevalence of the treatment actually
received. For trimming, weights were set equal to 0.10
if the stabilized weight was <0.10 and set equal to 10 if
it was >10. Findings were considered signiﬁcant at
p < 0.05. All statistical analyses were performed with
SAS (version 9.2, SAS Inc., Cary, North Carolina).
RESULTS
BASELINE AND PROCEDURAL DATA. Baseline char-
acteristics are summarized in Table 1. The lesion
and procedural characteristics are presented in
Table 2. Most of the treated lesions were Trans-
Atlantic Inter-Societal Consensus (TASC) II C or D
lesions with a mean length of 25  8 cm. There were
more patients with TASC II C/D lesions in the spot
stenting group. However, the lesion length, the le-
sions involving the popliteal artery including P2 or
P3 segment, and pre-procedural ABI did not differ
between groups.
All of the 129 limbs in the spot stenting group
achieved technical success. In 5 limbs of the long
stenting group, spot stenting was initially attemp-
ted; however, remaining ﬂow-limiting dissection
after the ﬁrst stenting required conversion to the
long stenting strategy. The other 62 limbs treated
with long stenting showed technical success. Lower
numbers of stents were implanted, and the stented
length was shorter in the spot stenting group. More
stents with larger diameters were implanted in the
spot stenting group. However, the stent-to-artery
ratio was similar between groups. Although only 9
limbs (7%) in the spot stenting group had distalpopliteal artery coverage, 38 limbs (56%) in the
long stenting group were covered in the popliteal
artery segment with stents. In particular, 15 limbs
(22%) of the long stenting group were distally
covered up to the P2 or P3 segment with stents.
The immediate procedural results are shown in
Table 3. Post-procedural ABI were similarly increased
in both groups (p ¼ 0.262). There were no procedure-
related deaths. Distal embolization to the distal SFA
or arterial perforation was observed at similar fre-
quencies in both groups.
PRIMARY PATENCY AND CLINICAL OUTCOMES,
ACCORDING TO STENTING STRATEGIES. During the
median follow-up period of 1.7 years, loss of patency
TABLE 3 Immediate Procedural Results and Stent Fractures
During Follow-Ups
Spot
Stenting
129 Limbs
Long
Stenting
67 Limbs p Value* p Value†
Post-procedural ABI 0.82  0.18 0.86  0.18 0.262 0.281
Immediate procedural
complications
Procedure-related
deaths
0 0 1.000 1.000
Distal embolization 7 (5) 2 (3) 0.721 0.446
Arterial perforation 2 (2) 1 (2) 1.000 0.975
Stent fracture‡ 0.405 0.196
No fracture 38 (78) 18 (67)
Type 1 5 (10) 3 (11)
Type 2 2 (4) 3 (11)
Type 3 4 (8) 2 (7)
Type 4 0 1 (4)
Type 5 0 0
Values are mean  SD or n (%). *For limb basis analysis. †For patient basis analysis
and derived from generalized estimating equations. ‡Follow-up x-rays for stent
fracture evaluation were available for 49 lesions in the spot stenting group and
27 lesions in the long stenting group.
ABI ¼ ankle-brachial index.
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476was found in 67 limbs. In the spot stenting group, 37
limbs (29%) showed restenosis: type 1 in 4 limbs
(11%); type 2 in 10 limbs (27%); and type 3 in 23 limbs
(62%) (Figure 1). In the long stenting group, 30 limbs
(45%) developed restenosis: type 1 in 2 limbs (7%);
type 2 in 9 limbs (30%); and type 3 in 19 limbs (63%)
(Figure 1). The frequencies of different restenotic
patterns were similar between groups (p ¼ 0.830).
Fluoroscopic or x-ray images for the evaluation of
stent fracture at the 12-month follow-up wereFIGURE 1 Restenotic Patterns
Restenotic patterns were similar between groups (p ¼ 0.830).available for 76 limbs (39%). There were no signiﬁcant
differences in the incidence and type of stent frac-
tures between groups (Table 3).
The Kaplan-Meier survival curves and adjusted
survival curves demonstrated that the spot stenting
group had signiﬁcantly higher primary patency rates
than the long stenting group did (Figures 2A and 2D).
Adjusted-patency rates at 1 and 2 years were 87% and
77% for the spot stenting group and 56% and 47% for
the long stenting group, respectively.
Of the 67 limbs that developed restenosis during
the follow-up, 39 and 8 limbs were treated with
repeat percutaneous revascularization and bypass
surgery, respectively. Twenty limbs were treated
medically because of patient refusal (n ¼ 6), poor
medical conditions (n ¼ 5), or mild symptoms (n ¼ 9).
Percutaneous revascularization was successful in 37
of 39 limbs (95%). The revascularization attempt
failed in 2 limbs, because the wire could not be passed
through the totally reoccluded lesions. The Kaplan-
Meier survival curves and adjusted survival curves
showed that the spot stenting group showed signiﬁ-
cantly higher TLR-free survival rates at 1 and 2 years
than the long stenting group did (91% and 84% vs.
61% and 52% after adjustment, p < 0.001) (Figures 2B
and 2E).
MULTIVARIATE ANALYSIS OF THE PREDICTORS OF
RESTENOSIS. The body mass index, critical limb
ischemia, nonuse of clopidogrel, distal run-off vessels
#1, small stent diameter, lower post-procedural ABI,
stent coverage of the popliteal artery extending to the
P2 or P3 segment, and long stenting were found to be
associated with an increased risk of restenosis as
FIGURE 2 Kaplan-Meier Survival Curves and Adjusted Survival Curves Using IPTW
The spot stenting group had higher (A) primary patency rates and (B) target lesion revascularization (TLR)-free survival rates than the long stenting group. There was a
graded relationship between the primary patency and the extent of popliteal artery coverage (C). These ﬁndings were consistent after adjustment using inverse
probability of treatment weighting (IPTW) (D–F).
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477determined via univariate analysis (Figure 3). On the
multivariate analysis, long stenting (hazard ratio
[HR]: 1.97) was identiﬁed as an independent predictor
of restenosis, along with the nonuse of clopidogrel
(HR: 3.25) or nonuse of cilostazol (HR: 2.23),
small stent diameter (HR: 0.64), distal run-off
vessels #1 (HR: 1.85), and post-procedural ABI (HR:
0.06) (Table 4). In the second model, long stenting
extending to the P2 or P3 popliteal artery segments,
compared with spot stenting, was associated with
3.37-fold (p ¼ 0.008) increases in the risk of reste-
nosis. The Kaplan-Meier survival curve also showed
a graded relationship between the primary patency
and the extent of popliteal artery coverage (p <
0.001) (Figures 2C and 2F). When adjusted by inverse
probability of treatment weighting, long stenting
extending to the P2 or P3 popliteal artery segments,
compared with spot stenting, was associated with
7.51-fold increases in the risk of restenosis (Table 4).
Findings of clustered Cox regression were consistent
(Online Table 1).DISCUSSION
The principal ﬁndings of the present study are that
the primary patency and the freedom of TLR were
signiﬁcantly lower with long stenting than with spot
stenting following intentional subintimal approach
for long femoropopliteal CTO. The risk of restenosis
was signiﬁcantly higher when long stenting was
extended to cover the P2 or P3 segment of the popli-
teal artery.
LONG STENTING FOR FEMOROPOPLITEAL OCCLUSIONS.
Recent randomized trials have mostly focused on
short-to-medium lesions, and results from these
trials have demonstrated higher patency in primary
self-expanding nitinol stenting than in provisional
stenting, particularly for increasing lesions of femo-
ropopliteal arteries (1–3). However, the majority of
lesions in clinical practice are considerably longer,
and whether the beneﬁt of primary stenting could be
extended to longer CTO with TASC II C/D lesions has
FIGURE 3 Univariate Analysis of Risk Factors for Restenosis
The circles represent the hazard ratios (HR). The error bars show the 95% conﬁdence intervals (CI). ABI ¼ ankle-brachial index;
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker.
TABLE 4 Multivariate Analysis of the Predictors of Restenosis
Multivariable Adjusted* Adjusted by IPTW
Model 1 Model 2 Model 1 Model 2
HR p Value HR p Value HR p Value HR p Value
Body mass index 0.95 0.150 0.95 0.192 — —
Critical limb ischemia 1.25 0.463 1.20 0.550 — —
Nonuse of clopidogrel 3.25 0.001 2.90 0.013 — —
Nonuse of cilostazol 2.23 0.007 2.12 0.013 — —
Nonuse of ACE inhibitor
or ARB
1.73 0.084 1.71 0.090 — —
Stent diameter, mm 0.64 0.044 0.69 0.105 — —
Distal run-off vessels #1 1.85 0.039 1.88 0.040 — —
Post-procedural ABI 0.06 <0.001 0.07 <0.001 — —
Stenting strategies
Spot stenting (reference) 1.00 1.00 1.00 —
Long stenting 1.97 0.023 — 3.26 <0.001 —
Long stenting limited
to femoral artery
— 1.79 0.133 — 2.00 0.021
Long stenting extended
to P1
— 1.64 0.228 — 2.36 0.002
Long stenting extended
to P2 or P3
— 3.37 0.008 — 7.51 <0.001
Dashes indicate that data were not available. *Adjusted for variables achieving p < 0.1 in the univariate analysis.
HR ¼ hazard ratio; IPTW ¼ inverse probability of treatment weights; other abbreviations as in Table 1.
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478not been proven. In the present study, which reﬂects
clinical practice, we compared spot stenting with long
stenting in long femoropopliteal CTO with mean
lesion lengths of 25  8 cm and 94% TASC II C/D
lesions. Although there are limited data on the out-
comes of stenting after subintimal angioplasty,
especially for femoropopliteal CTO, registry data
show that longer stenting is associated with poor
outcomes. Bouﬁ et al. (6) reported that the implan-
tation of stents covering the whole subintimal tract
does not beneﬁt primary patency. Siablis et al. (9)
found a >6-fold increase in restenosis with full-
lesion stenting. Moreover, Treiman et al. (15) re-
ported that the primary patency was 85% at 1 year but
only 18% at 3 years when they routinely stented the
entire length of the dissection after subintimal an-
gioplasty. Here, we found that the primary patency
and the freedom of TLR were signiﬁcantly lower with
long stenting than with spot stenting after subintimal
angioplasty. Adjusted-patency rate was 47%, and the
TLR-free survival rate was 52% at 2 years for the
long stenting group, which is similar to the ﬁndings
of a previous report (15).
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479IMPLICATION OF LONG STENTING AS A RISK
FACTOR OF RESTENOSIS. The nonuse of cilostazol
or clopidogrel, poor distal run-off vessels, and lower
post-procedural ABI were found to be independent
predictors for restenosis, and these results are similar
to previous reports (9,10,16). Larger stent diameter
may be more advantageous to obtain larger lumen
of the subintimal tract and to maintain the femoral
patency after intentional subintimal approach.
In the present study, long stenting was identiﬁed
as an independent predictor of restenosis. Theoreti-
cally, longer lesion length, increased fracture rate,
small artery or stent diameter, or the stent-to-artery
diameter mismatch may lead to a higher restenosis
rate in the long stenting group than in the spot
stenting group. However, we found no signiﬁcant
differences regarding these variables. Whether the
stent fractures are generally associated with poor
outcomes is still controversial (12,17). We did not
routinely investigate for stent fractures. Therefore,
the stent fracture rates in our study may have been
inaccurate. Additionally, the small sample size may
have led to insigniﬁcant difference in stent fracture
rates between groups. Interestingly, we found that
the longer extent of stent coverage into the popliteal
artery, especially those that involved the P2 or P3
segment, was independently associated with a
3.37-fold increased restenosis rate. This is compatible
with the previous observation that popliteal stenting
in TASC II D lesions was associated with a 4.28-fold
increased risk of restenosis (18). A randomized
controlled trial demonstrated superior outcomes of
primary stenting for the treatment of isolated popli-
teal artery lesions compared with provisional stenting
(19). However, this study included only isolated
popliteal artery disease and the mean target lesion
length was 42 mm. Recent studies suggested that
longer stents may cause more kinking in the adjacent
vessel segments and also more increased wall shear
stress due to the axial and radial rigidity of the
stented segment (20,21). These biomechanical
changes by long stents may be also responsible for the
increased restenosis risk.In order to avoid problems related to a metal
scaffold left behind in the popliteal artery segment, a
drug-coated balloon with or without atherectomy
may be a more favorable treatment option for the
distal segment of the femoropopliteal artery. Also,
drug-coated balloons combined with spot stenting
may be advantageous for the treatment of long fem-
oropopliteal CTO after subintimal recanalization (22).
The placement of a new self-expanding interwoven
nitinol stent (SUPERA, IDEV Technologies, Webster,
Texas) may be another favorable option for the
treatment of popliteal lesions (11).
STUDY LIMITATIONS. First, this was a retrospective
study of single-center registry data from a relatively
small group of patients. Second, noninvasive testing
during the follow-ups was less rigorously carried out
than would be achieved in a prospective study. Third,
there was no pre-deﬁned limit of stented length for
spot stenting. Fourth, we did not perform intravas-
cular ultrasound during the procedure to prove the
subintimal passage of the wires. Therefore, we use
the term “intentional subintimal approach” rather
than “subintimal angioplasty.” However, the sub-
intimal approach is a commonly performed procedure
for long CTO of the femoropopliteal artery. Only a
small number of operators use intravascular ultra-
sound in daily practice.CONCLUSIONS
The primary patency was signiﬁcantly higher with
spot stenting than with long stenting following
intentional subintimal approach for long femo-
ropopliteal CTO. The risk of restenosis was especially
higher when long stenting was extended to the distal
popliteal artery.
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